Abstract: AIM: To approach the clinical therapeutic effects of artesunate united Primaquine in the treatment of delay or recrudescence malaria.METHODS: 82 patients were randomly divided into two groups.Patients of the treatment group(n=41)were given an initial dose of 2.4 mg/kg artesunate i.v., 12 h later,a second dose of 1.2 mg/kg artesunate was given in the same way.For the succeeding 6 days,a daily dose of 1.2 mg/kg artesunate was given in the same manner to each patient in the treatment group;and each of the patients were given Primaquine tables 22.5 mg/d, p.o..The control group(n=41)were given an initial dose of 20 mg of quinimax i.v.,12 h later,a second dose of 10 mg/kg quinimax was given in the same way.Thereafter,10 mg/kg of quinimax was given q.12.h.In the same manner until the patients could take medicines by mouth.Quinimax tablets in a dose of 10 mg/kg were then given q.8.h. The course of treatment was 7 d.RESULTS: After 7 and 28 d,the cure rates in the treatment and control group were 97.5％, 95.1％;97.5%,90.2%,respectively.The changes in the treatment and control group were similar(P>0.05). The defervescence time was 28.0 and 51.6 h,and the clearing time of haemoplasmodium was 30.4 and 59.5 h in the treatment and control group,respectively;the differences was significant(P<0.01).CONCLUSION: Artesunate united Primaquine was found to act more quickly in the treatment of pernicious delay or recrudescence malaria,low recurrence rate,with only mild side effects.It is also effective in the treatment of malaria caused by quinine-resistant strains of malaria parasites.It should be the drug of first choice in the treatment of malaria that quinine fails to effect a cure.

Key words: Artesunate, Primaquine, Quinimax, Malaria  ,  ,  ,  ,